Raydiax Secures €7.5M for Revolutionary Cancer Therapy CT Scanner
March 15, 2026, 9:33 am
Raydiax, a German med-tech innovator, closed a €7.5 million Series A1 funding round. This vital capital accelerates its TACT CT scanner. TACT offers groundbreaking real-time imaging directly within operating rooms. It precisely guides minimally invasive cancer therapies. The system drastically improves surgical accuracy, minimizes complications, and shortens patient recovery. Funds will initiate critical first-in-human studies, scale production readiness, and prepare for a strategic market launch. This significant investment is poised to revolutionize interventional oncology, enhancing cancer patient outcomes and global medical practice through advanced deep-tech.
A significant investment boosts medical innovation. Raydiax, a German medical technology firm, announced a successful Series A1 funding round. The company secured €7.5 million. This capital injection will propel its TACT system towards market readiness. TACT is a therapy assistance CT scanner. It promises to transform minimally invasive cancer treatments.
The funding round saw substantial contributions. €5 million came from venture capital. Existing business angels reaffirmed their commitment. bmp Ventures, through its IBG funds, participated. The GETEC Family Office of Dr. Karl Gerhold also invested. An additional €2.5 million arrived from the European Commission. This came via the highly selective EIC Accelerator program. This dual funding stream underscores TACT's potential and perceived market value.
Raydiax plans strategic deployment of these funds. A primary objective is to initiate first-in-human studies for TACT. This crucial step generates early clinical evidence. The company will also continue development. Its goal is production readiness. Organizational capabilities will expand. This includes sales, manufacturing, and quality management. Preparations for initial commercial installations are underway. This comprehensive approach targets a seamless market entry.
The TACT system represents a paradigm shift. It supports therapy planning, execution, and monitoring. All these functions occur within a single, integrated imaging platform. TACT is tailored for interventional oncology procedures. This distinguishes it from traditional CT scanners. Conventional units typically reside in radiology departments. They are primarily for diagnostic imaging. Raydiax's system integrates directly into operating rooms. It assists physicians during minimally invasive treatments.
Minimally invasive cancer therapies offer numerous advantages. They reduce complications. Procedure times often shorten. Patients experience faster recovery. This contrasts sharply with traditional surgical approaches. TACT enhances these benefits. It provides real-time imaging during procedures. This expands the scope of treatments achievable with minimally invasive techniques. Surgeons gain unparalleled precision.
The technology behind TACT is advanced. It allows focused live CT imaging. This innovation significantly reduces radiation exposure. Both patients and physicians benefit. Procedure times in the operating room also decrease. TACT features a larger CT gantry opening. This design innovation holds immense promise. It enables new surgical methods. Robotic-assisted procedures, for instance, become more feasible. This opens doors to future advancements in surgical oncology.
Raydiax emerged from a strong academic background. It is a spin-off from the STIMULATE research campus. This campus is part of the Otto von Guericke University Magdeburg. The company was founded in 2022. Its headquarters are in Magdeburg’s Science Harbor. This origin highlights a foundation in rigorous scientific research. The founding team’s expertise stems from this collaborative initiative. STIMULATE focuses on image-guided minimally invasive medicine.
The new financing marks a critical juncture for Raydiax. It moves from technology development to clinical application. Regulatory approval is a clear next step. Broader commercialization will follow. The company aims to establish TACT as a new device category. This category will serve minimally invasive cancer therapies. The market segment for such solutions is growing.
This deep-tech innovation addresses a specific clinical need. Interventional oncology requires precise, real-time guidance. TACT delivers this capability. The system has the potential to significantly improve cancer patient care. Its robust scientific foundation is clear. The technical expertise of its founding team is recognized. Investors see strong technological maturity and market potential.
The EIC Accelerator program is highly selective. Raydiax's success in securing its grant is notable. This achievement, coupled with the Series A1 funding, validates the TACT system. It confirms its scientific excellence. The technological and clinical differentiation is evident. The entrepreneurial maturity of the team also stands out. This success sends a strong signal. Long-term medical technology research can lead to internationally competitive high-tech companies. These companies offer significant clinical and economic relevance.
Raydiax’s vision extends beyond initial market entry. The company aims for an international presence. The growing market for advanced medical devices provides fertile ground. TACT’s innovative features position it strongly. Its ability to enhance precision, safety, and efficiency in cancer treatment is compelling. The global fight against cancer demands such advanced tools. Raydiax is poised to deliver a transformative solution. This advancement promises better outcomes for countless patients worldwide.
A significant investment boosts medical innovation. Raydiax, a German medical technology firm, announced a successful Series A1 funding round. The company secured €7.5 million. This capital injection will propel its TACT system towards market readiness. TACT is a therapy assistance CT scanner. It promises to transform minimally invasive cancer treatments.
The funding round saw substantial contributions. €5 million came from venture capital. Existing business angels reaffirmed their commitment. bmp Ventures, through its IBG funds, participated. The GETEC Family Office of Dr. Karl Gerhold also invested. An additional €2.5 million arrived from the European Commission. This came via the highly selective EIC Accelerator program. This dual funding stream underscores TACT's potential and perceived market value.
Raydiax plans strategic deployment of these funds. A primary objective is to initiate first-in-human studies for TACT. This crucial step generates early clinical evidence. The company will also continue development. Its goal is production readiness. Organizational capabilities will expand. This includes sales, manufacturing, and quality management. Preparations for initial commercial installations are underway. This comprehensive approach targets a seamless market entry.
The TACT system represents a paradigm shift. It supports therapy planning, execution, and monitoring. All these functions occur within a single, integrated imaging platform. TACT is tailored for interventional oncology procedures. This distinguishes it from traditional CT scanners. Conventional units typically reside in radiology departments. They are primarily for diagnostic imaging. Raydiax's system integrates directly into operating rooms. It assists physicians during minimally invasive treatments.
Minimally invasive cancer therapies offer numerous advantages. They reduce complications. Procedure times often shorten. Patients experience faster recovery. This contrasts sharply with traditional surgical approaches. TACT enhances these benefits. It provides real-time imaging during procedures. This expands the scope of treatments achievable with minimally invasive techniques. Surgeons gain unparalleled precision.
The technology behind TACT is advanced. It allows focused live CT imaging. This innovation significantly reduces radiation exposure. Both patients and physicians benefit. Procedure times in the operating room also decrease. TACT features a larger CT gantry opening. This design innovation holds immense promise. It enables new surgical methods. Robotic-assisted procedures, for instance, become more feasible. This opens doors to future advancements in surgical oncology.
Raydiax emerged from a strong academic background. It is a spin-off from the STIMULATE research campus. This campus is part of the Otto von Guericke University Magdeburg. The company was founded in 2022. Its headquarters are in Magdeburg’s Science Harbor. This origin highlights a foundation in rigorous scientific research. The founding team’s expertise stems from this collaborative initiative. STIMULATE focuses on image-guided minimally invasive medicine.
The new financing marks a critical juncture for Raydiax. It moves from technology development to clinical application. Regulatory approval is a clear next step. Broader commercialization will follow. The company aims to establish TACT as a new device category. This category will serve minimally invasive cancer therapies. The market segment for such solutions is growing.
This deep-tech innovation addresses a specific clinical need. Interventional oncology requires precise, real-time guidance. TACT delivers this capability. The system has the potential to significantly improve cancer patient care. Its robust scientific foundation is clear. The technical expertise of its founding team is recognized. Investors see strong technological maturity and market potential.
The EIC Accelerator program is highly selective. Raydiax's success in securing its grant is notable. This achievement, coupled with the Series A1 funding, validates the TACT system. It confirms its scientific excellence. The technological and clinical differentiation is evident. The entrepreneurial maturity of the team also stands out. This success sends a strong signal. Long-term medical technology research can lead to internationally competitive high-tech companies. These companies offer significant clinical and economic relevance.
Raydiax’s vision extends beyond initial market entry. The company aims for an international presence. The growing market for advanced medical devices provides fertile ground. TACT’s innovative features position it strongly. Its ability to enhance precision, safety, and efficiency in cancer treatment is compelling. The global fight against cancer demands such advanced tools. Raydiax is poised to deliver a transformative solution. This advancement promises better outcomes for countless patients worldwide.